Real-World Experience of Imipenem-Relebactam Treatment as Salvage Therapy in Difficult-to-Treat Pseudomonas aeruginosa Infections (IMRECOR Study)
Machuca, I. (Centro de Investigación Biomédica en Red de Enfermedades Infecciosas)
Domínguez, A. (Hospital Universitario Reina Sofía (Córdoba, Espanya))
Amaya, R. (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia))
Arjona, C. (Instituto Maimónides de Investigación Biomédica de Córdoba)
Gracia-Ahufinger, I. (Hospital Puerta del Mar (Cadis))
Carralon, M. (Hospital Quirón de Pozuelo)
Giron, R. (Hospital Universitario de la Princesa (Madrid))
Gea, I. (Hospital de Jaén)
Benito, Natividad (Institut de Recerca Sant Pau)
Martin, A. (Hospital Puerta del Mar (Cadis))
Galan, F. (Hospital Puerta del Mar (Cadis))
Martinez, Jose Antonio (Hospital Clínic i Provincial de Barcelona)
Iglesias, R. (Hospital General de Granollers)
Revuelto, J. (Hospital Puerta del Mar (Cadis))
Caston, J.J. (Centro de Investigación Biomédica en Red de Enfermedades Infecciosas)
Cano, Amanda (Centro de Investigación Biomédica en Red de Enfermedades Infecciosas)
Ruiz-Arabi, E. (Centro de Investigación Biomédica en Red de Enfermedades Infecciosas)
Martínez-Martínez, L. (Universidad de Córdoba)
Torre-Cisneros, J. (Universidad de Córdoba)
Universitat Autònoma de Barcelona

Date:	2025
Abstract:	Introduction: Difficult-to-treat-resistant (DTR) infections caused by Pseudomonas aeruginosa represent a global public health threat, prioritizing the search and development of new antibiotics for this microorganism. Methods: We present the real-life experience of the compassionate use of imipenem/cilastatin/relebactam in a descriptive study involving 14 patients with DTR-P. aeruginosa infection and limited treatment options. Results: The primary source of infection was skin and soft tissue infection, 57. 1% (8/14), followed by respiratory infection-pneumonia, 28. 6% (4/14). At the onset of infection, 71. 4% (10/14) of patients were in the intensive care unit (ICU). All our patients had a Charlson Score of ≥ 3. Septic shock was observed in 64. 3% (9/14) of patients. The median treatment duration was 15 days, and no patient experienced an adverse event that required treatment interruption. All-cause 30-day mortality was observed in 42. 9% of cases (6/14), while clinical efficacy and microbiological success were observed in 64. 3% (9/14). Conclusions: Imipenem/cilastatin/relebactam may represent a treatment option for patients with DTR-P. aeruginosa infections, which should be validated in prospective clinical trials.
Rights:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original.
Language:	Anglès
Document:	Article ; recerca ; Versió publicada
Subject:	Pseudomonas aeruginosa ; Carbapenem ; Cilastatin ; Imipenem ; Multidrug ; Relebactam ; Resistant
Published in:	Infectious Diseases and Therapy, Vol. 14 Núm. 1 (january 2025) , p. 283-292, ISSN 2193-6382

DOI: 10.1007/s40121-024-01077-z
PMID: 39612160

10 p, 347.7 KB

The record appears in these collections:
Research literature > UAB research groups literature > Research Centres and Groups (research output) > Health sciences and biosciences > Institut de Recerca Sant Pau
Articles > Research articles
Articles > Published articles